<DOC>
	<DOC>NCT01613248</DOC>
	<brief_summary>The purpose of this study is to assess the effectiveness, safety and tolerability of a range of doses of MK-1602 versus placebo in the treatment of acute migraine.</brief_summary>
	<brief_title>A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>&gt; 1 year history of migraine with or without aura as defined by International Headache Society (IHS) criteria 1.1 and/or 1.2 Migraines typically last between 4 to 72 hours, if untreated ≥ 2 and ≤ 8 moderate or severe migraine attacks per month in each of the two months prior to screening Male, female who is not of reproductive potential, or female of reproductive potential with a screening serum βhuman chorionic gonadotropin (βhCG) level consistent with a notpregnant state, and who agrees to use acceptable contraception Pregnant or breastfeeding, or is a female expecting to conceive within the projected duration of study participation Participant has difficulty distinguishing his/her migraine attacks from tensiontype headaches History of predominantly mild migraine attacks or migraines that usually resolve spontaneously in less than two hours More than 15 headachedays per month or has taken medication for acute headache on more than 10 days per month in any of the three months prior to screening Basilartype or hemiplegic migraine headache &gt; 50 years old at age of migraine onset Taking migraine prophylactic medication where the prescribed daily dose has changed during the 3 months prior to screening and will not be changed during the study Taking a proton pump inhibitor (PPI) or a histamine receptor 2 (H2) blocker on a daily or near daily basis (&gt; 3 days per week) Taking the following medications from 1 month prior to screening through study period: potent cytochrome P450 (CYP) 3A4 inhibitors (e.g., cyclosporine, itraconazole, ketoconazole, fluconazole, erythromycin, clarithromycin, nefazodone, telithromycin, cimetidine, quinine, diltiazem, verapamil, and human immunodeficiency virus [HIV] protease inhibitors), moderate or marked CYP3A4 inducers (e.g., rifampicin, rifabutin, barbiturates [e.g., phenobarbital and primidone], systemic glucocorticoids, nevirapine, efavirenz, pioglitazone, carbamazepine, phenytoin, and St. Johns wort), or drugs with narrow therapeutic margins and potential for drug interactions in the CYP2C family (e.g., warfarin) Participant is unable to refrain from consumption of grapefruit or grapefruit juice during study History of hypersensitivity to, or has experienced a serious adverse event in response to 3 or more classes of drugs (prescription and overthecounter) Clinical or laboratory evidence of uncontrolled diabetes, human immunodeficiency virus (HIV) disease, or significant pulmonary, renal, hepatic, endocrine, or other systemic disease Other confounding pain syndromes, psychiatric conditions such as uncontrolled major depression, dementia or significant neurological disorders other than migraine. Patients who are currently being treated with nonprohibited medication for depression and symptoms are well controlled are eligible to participate Participant is at imminent risk of selfharm History of malignancy ≤ 5 years prior to study, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer History of gastric or small intestinal surgery (including gastric bypass surgery or banding), or presence of a disease that causes malabsorption Participant has recent history (within the last year) of drug or alcohol abuse or dependence or is a user of recreational or illicit drugs Participant is legally or mentally incapacitated Donation of blood products or phlebotomy of &gt; 300 ml within 8 weeks of study, or intent to donate blood products or receive blood products within 30 days of screening and throughout study Intent to donate eggs or sperm within the projected duration of the study Current participation in or participation within 30 days of screening in a study with an investigational compound or device Previous exposure to MK0974 and/or MK3207 Use within the past 2 months of an opioid or barbituratecontaining analgesic for migraine relief Inpatient or emergency department treatment of an acute migraine attack within the past 2 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>